KALA · NASDAQ
KALA Bio (KALA) Stock Price & Fundamentals
KALA Bio (KALA) closed at $1,312.36 on Oct 9, 2026, up 0.93% from the previous close of $1,300.25.
Share price, past year
1Y +30.46%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,312.36 |
| Sep 30, 2026 | $1,270.68 |
| Aug 31, 2026 | $1,183.89 |
| Jul 31, 2026 | $1,123.73 |
| Jun 30, 2026 | $1,131.93 |
| May 29, 2026 | $1,108.22 |
| Apr 30, 2026 | $1,117.84 |
| Mar 31, 2026 | $1,082.53 |
| Feb 27, 2026 | $1,051.08 |
| Jan 30, 2026 | $1,122.65 |
| Dec 31, 2025 | $1,124.56 |
| Nov 28, 2025 | $1,011.71 |
| Oct 31, 2025 | $1,019.29 |
Key statistics
- Market cap
- $25.38B
- P/E (TTM)
- —
- EPS (TTM)
- −$30.83
- Revenue (TTM)
- —
- Net income (TTM)
- −$10.08M
- Shares outstanding
- 19.3M
- Dividend yield
- —
- 52-week range
- $990.16 – $1,312.36
KALA Bio's market cap is $25.38B, based on a share price of $1,312.36 and 19.3M shares outstanding as of Jun 30, 2026.
Financials
KALA Bio reported revenue of $0.00 for fiscal 2025.
KALA Bio reported a net loss of $26.98M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$26.98M | — | −$165.50 | — |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$38.51M | — | −$507.50 | — |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$42.20M | — | −$867.50 | — |
| FY2022ended Dec 31, 2022 | $3.89M | −65.4% | −$44.82M | −1,151.6% | −$1,474.00 | — |
| FY2021ended Dec 31, 2021 | $11.24M | +76.7% | −$142.61M | −1,268.7% | −$5,416.00 | — |
| FY2020ended Dec 31, 2020 | $6.36M | +4.7% | −$104.33M | −1,639.9% | −$4,975.00 | — |
| FY2019ended Dec 31, 2019 | $6.07M | — | −$94.35M | −1,553.3% | −$6,900.00 | −$94.06M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$42.21M | — | −$9,275.00 | −$34.58M |
| FY2016ended Dec 31, 2016 | $0.00 | −100.0% | −$33.17M | — | −$70,175.00 | −$27.50M |
| FY2015ended Dec 31, 2015 | $45.00K | — | — | — | — | −$15.34M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $420.00K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $2.10M | — | — |
| Q1 FY2022ended Mar 31, 2022 | $1.37M | — | — |
| Q4 FY2021ended Dec 31, 2021 | $1.86M | — | — |
| Q3 FY2021ended Sep 30, 2021 | $3.07M | — | — |
| Q2 FY2021ended Jun 30, 2021 | $3.05M | — | — |
| Q1 FY2021ended Mar 31, 2021 | $3.27M | — | — |
Company profile
- Name
- KALA BIO, Inc.
- Ticker
- KALA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1167 Massachusetts Avenue, Arlington, MA 02476
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001479419
Recent SEC filings
- Sep 10, 2026
- Sep 9, 2026
- Aug 28, 2026
- Aug 19, 2026
- Jul 23, 2026
- May 15, 2026
- May 7, 2026
- Apr 15, 2026
Frequently asked questions
What is KALA Bio's stock price?
KALA Bio (KALA) closed at $1,312.36 on Oct 9, 2026, up 0.93% from the previous close of $1,300.25.
What is KALA Bio's market cap?
KALA Bio's market cap is $25.38B, based on a share price of $1,312.36 and 19.3M shares outstanding as of Jun 30, 2026.
How much revenue does KALA Bio make?
KALA Bio reported revenue of $0.00 for fiscal 2025.
Does KALA Bio pay a dividend?
KALA Bio's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from KALA BIO, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures